Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.79 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031880 | 0.89 | AR (0.82) | ARCRBNSMYD3USP30PGR | |
| SCHEMBL25905202 | 0.85 | AR (0.71) | ARCRBNUSP30PGRCYP2D6 | |
| SCHEMBL24031884 | 0.85 | AR (0.80) | ARCRBNSMYD3MAPK14PGR | |
| SCHEMBL24031878 | 0.85 | AR (0.80) | ARCRBNSMYD3MAPK14USP30 | |
| SCHEMBL25905098 | 0.84 | AR (0.56) | ARCRBNSMYD3MAPK14USP30 | |
| SCHEMBL24031883 | 0.83 | AR (0.77) | AR | |
| SCHEMBL26801765 | 0.81 | AR (0.74) | ARMAPK14PGRCYP2D6CYP2C9 | |
| SCHEMBL26802787 | 0.81 | AR (0.74) | ARCRBNPGRCYP2D6CYP2C9 | |
| SCHEMBL25318479 | 0.81 | AR (0.93) | ARCRBN | |
| SCHEMBL25317228 | 0.81 | AR (0.93) | ARCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2022011205-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | AR, SHBG, CYP19A1 | AR 1/4885CRBN 945/4885SMYD3 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.